Could Oral Paclitaxel Plus Encequidar Be Offered as Outpatient mBC Treatment?
Gerardo Umanzor, MD, explains the potential benefits of oral paclitaxel and encequidar compared with the intravenous formulation for the treatment of metastatic breast cancer during the coronavirus disease 2019 pandemic.
Gerardo Umanzor, MD, medical oncologist with Centro Oncologico Integral in San Pedro Sula, Honduras, explains the potential benefits of oral paclitaxel and encequidar compared with the intravenous (IV) formulation for the treatment of metastatic breast cancer during the coronavirus disease 2019 (COVID-19) pandemic.
In the phase 3 KX-ORAX-001 clinical trial (NCT02594371), progression-free survival (PFS) and overall survival (OS) improvement were achieved with the combination of oral paclitaxel plus encequidar versus intravenous paclitaxel plus encequidar. Umanzor says that considering the limitations of access to care during the pandemic, the idea of an outpatient treatment option is appealing for both physicians and patients.
A shift from IV infusions may also be a more cost-effective strategy for treating patients explains Umanzor, because inpatient care tends to be more costly compared with outpatient care.
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
November 13th 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
